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Abstract
Background: The aim was to assess the risk of venous thromboembolism (VTE) associated with use of combined
oral contraceptives (COCs) in women with a family history of VTE.
Methods: The study is a Swedish nationwide case-control study based on the Multigeneration register, the
Swedish Hospital Discharge Register, the Outpatient Care Register, and the Swedish Prescribed Drug Register.
Cases (n = 2,311) were non-pregnant Swedish women aged 15-49 with first VTE diagnoses between January
2006 and December 2010. Five controls without VTE were matched to each case on age and education level.
Conditional logistic regression examined the associations with VTE with determination of odds ratio (OR) for
first VTE diagnosis. Effect modification was assessed by interaction testing.
Results: Both among controls (14.6 % vs. 4.5 %; p < 0.0001) and cases (27.2 % vs. 8.8 %; p < 0.0001) COC use
was more common in women without a family history of VTE compared with women with a family history of
VTE. In a multivariate conditional logistic regression model the OR for VTE was 2.53 (95 % CI 2.23-2.87) for
COC users and 2.38 (2.09-2.71) for individuals with a family history of VTE. The OR for VTE for COC users with
a family history of VTE was 6.02 (5.02-7.22). There was no significant interaction between family history of VTE
and COC use (OR 0.92, 0.57-1.46).
Conclusions: Family history of VTE is a risk factor for VTE in women using COCs. The low prevalence of COC
use among women with a family history of VTE suggests that family history of VTE is considered when COCs
are prescribed in Sweden. The present study may therefore even underestimate the importance of family
history of VTE. The lack of interaction indicates that the risk of COC use in women with family history of VTE
is determined by the product of the ORs for family history and COC use.
Keywords: Oral contraceptives, Venous thromboembolism, Epidemiology, Genetics
Introduction
The first report of an increased risk of venous thrombosis
associated with oral contraceptives appeared in 1961 [1].
Since then, several large studies have confirmed a two-
fold to six-fold increased risk of deep venous thrombosis
associated with current oral contraceptive use [2–15]. The
thrombotic risk of oral contraceptives is dependent on
the oestrogen dose and type of progestogen [16]. The
risk of venous thromboembolism (VTE) in women
using combined oral contraceptives (COCs) is attrib-
uted to changes in haemostasis [17]. These changes
may have a greater impact in women with inherited
thrombophilic defects (antithrombin deficiency, pro-
tein C deficiency, protein S deficiency, factor V Leiden)
[18–26]. While the absolute risks for VTE among
healthy women using COC are low, their use by
women with inherited thrombophilic defects can pose
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significantly increased health risks. Recognizing this
increased VTE risk, WHO recommends against use of
COCs among women with these conditions. However,
because of the low prevalence of thrombophilic defects
and the high cost of screening, routine assessments for
these conditions are not endorsed by WHO [27]. Sev-
eral reports have investigated whether family history of
VTE could be used to identify women with thrombo-
philic defects, but the sensitivity and specificity of
finding thrombophilic defects are too low [28, 29]. In
fact, Bezemar found that only 30 % of patients with a
family history of VTE have an identified thrombophilic
defect [30].
Several studies have shown that family history of VTE is
a common and strong risk factor for VTE even in the ab-
sence of known thrombophilic defects [30–33]. Moreover,
family history of VTE is more strongly related to shared
biological (genetic) factors than to environmental factors
[34, 35]. In a study of 50 women with VTE using oral con-
traceptives, 16 % had a family history of VTE [36]. In a
case-control study of women with VTE aged 18-64 years,
self-reported family history of VTE in combination with
COC use gave a very high odds ratio of (OR) for VTE of
15.3 (95 % confidence interval [CI] = 6.1-38), compared
with non-users without a family history of VTE [37]. Po-
tential drawbacks of this case-control study were the
possibility of recall bias, the inclusion of older women
who do not use COCs, and the failure to exclude women
who had been sterilized, or hysterectomized. No large na-
tionwide family study has determined whether the import-
ance of family history of VTE is a risk factor for VTE in
patients treated with COCs.
We assessed the risk of VTE in users of oral contra-
ceptives with a family history of VTE in Sweden using
nationwide registers. The aim was to determine the im-
portance of family history of VTE as a predictor for
VTE in women using COCs.
Material and methods
Details of ethics approval
The study was approved by the Ethics Committee of
Lund University, Sweden (approval number 409/2008,
with amendments approved on September 1 2009 and
January 22 2010). It was performed in compliance with
the Declaration of Helsinki. Consent was not obtained
but the presented data are anonymised and there is no
risk of identification.
Settings
We linked comprehensive register and health care data
from multiple nationwide Swedish sources to form a
database using the unique individual Swedish 10-digit
personal ID numbers assigned to all residents. These ID
numbers were replaced with serial numbers in order to
preserve confidentiality. Our database contained the fol-
lowing sources [38–42]: the Swedish Hospital Discharge
Register, which included all hospitalizations in Sweden
in 1964-2010; the Multi-Generation Register, which in-
cluded information on family relationships for all indi-
viduals born in Sweden in 1932 and later; the Swedish
Prescribed Drug Register, which included all prescrip-
tions in Sweden picked up by patients between July 1
2005 and December 31 2010; the Swedish Cause of
Death Register, which contained all causes of death and
times of death from 1961-2010; and the Outpatient Care
Register, which included information from outpatient
clinics covering all geographic regions in Sweden from
2001-2010.
Inclusion and exclusion criteria
The dataset for these analyses was created by identifying
from the Swedish Hospital Discharge Register and the
Outpatient Care Register all females aged 15-49 with diag-
noses of VTE during the period 2006 to 2010. We defined
VTE based on the following ICD-10 codes: I636 (cerebral
infarction due to cerebral vein thrombosis), I676 (cerebral
vein thrombosis), I80 (venous thrombosis of the lower ex-
tremities [except I80.0, i.e. superficial thrombophlebitis]),
I81 (portal vein thrombosis), I82 (other venous embolism
or thrombosis) and I26 (pulmonary embolism). We used
only main diagnoses to guarantee high validity (N = 7,795
VTE cases). Numbers of cases by each kind of venous
thromboembolism are presented in Table 1. Furthermore
we required that the patients retrieved from the pharmacy
an antithrombotic agent within 14 days from the date of
their VTE diagnosis (requirement 1). Antithrombotic
agents were defined according to the following ATC
codes: B01AA, B01AB (except B01AB02), B01AE, B01AF
and B01AX. We also required that both the father and
mother were registered in the Multi-Generation Register
(requirement 2). Individuals with previously registered
diagnoses of any type of VTE in the Swedish Hospital
Discharge Register (from 1964) and/or the Outpatient
Care Register (from 2001) were excluded (requirement 3).
Any type of VTE was defined by the ICD-7, ICD-8, ICD-9
and ICD-10 codes found in Additional file 1: Table S1
[32–35]. Individuals registered in the Swedish Hospital






I676 119 (2 %) 27 (1 %)
I80 4,545 (58 %) 1,156 (50 %)
I81 76 (1 %) 20 (1 %)
I82 1,143 (15 %) 358 (15 %)
I26 1,887 (24 %) 746 (32 %)
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Discharge Register with the following prior to their VTE
diagnosis were also excluded (requirement 4): Hysterec-
tomy (surgical procedure codes LCD, 7220, 7221, 7222
and 7223), Bilateral oophorectomy (surgical procedure
codes LAE20, LAE21, LAF10, LAF11, 7021, 7022, 7031
and 7032), Unilateral oophorectomy twice (surgical pro-
cedure codes LAF00, LAF01, 7020 and 7030), sterilization
(surgical procedure codes LGA00-LGA98, 7150, 7151,
and 7152), coronary heart disease (ICD10: I20-I25; ICD9:
410-414; and ICD8: 410-414), Heart failure (ICD10: I50,
ICD9: 428, ICD8: 428), or cerebrovascular disease (ICD10:
I60-I69; ICD9: 430-438; and ICD8: 430-438). The follow-
ing exclusion criteria were additionally applied: diagnosis
of any form of cancer in the Swedish Hospital Discharge
Register within 5 years before or 1 year after their VTE
diagnosis (cancer defined by the following ICD 10 codes:
C00-C99) (requirement 5); treatment for infertility (ATC
code G03G in the Swedish Prescribed Drug Register)
(requirement 6); registered pregnancy within 9 months
before or 3 months after the date of the VTE diagnosis
(requirement 7); women who stopped use of any contra-
ceptives prior to the VTE diagnosis according to the daily
defined dose (DDD) from last retrieved recipe (require-
ment 8). We defined contraceptives by the following ATC
codes: G03AA (except G03AA13) and G03AB. From the
date the individual retrieved the drug from the pharmacy
we used the DDD in order to calculate when they stopped
using the drug. For example, if an individual retrieved the
drug on January 1 2006 and the number of DDDs were 90
we considered the individual to have stopped using the
drug 90 days after January 1 2006. However, if an individ-
ual retrieved a new COC within the 90 day period or less
than 30 days after the 90 day period we continued to
consider the individual as a user of contraceptives until
the next period of use ended. Individuals who stopped
using contraceptives prior to their VTE were excluded
from the study. As the Prescribed Drug Register only con-
tains data from July 1 2005 onwards we used a 6 month
wash-out period. Hence, a VTE case could only be defined
from the January 1 2006. In total we included 2,409 cases
with VTE. In total, 5386 cases with VTE were excluded
due to the mentioned exclusion criteria. Numbers of cases
and controls excluded by each requirement (1-8) are
shown in Table 2.
Each case was matched to five controls based on year
of birth and education level. Socioeconomic data on
education correlate with lifestyle factors [39]. Adjusting
for education could help to diminish confounding by
lifestyle factors [39]. Education level was categorized into
three groups: low (0-9 years), middle (10-11 years) and
high (12 years or more). For individuals 25 years and
younger we selected the highest education level achieved
by either the mother or father. In order to be eligible to
be a control individual we applied the same criteria as
for cases (requirements 2-8). Furthermore, the control
individual had to be alive and registered in Sweden at
the time of the case’s VTE diagnosis. An individual could
only be selected as a control individual once. Moreover,
98 cases could not be matched to five controls and were
excluded from the analysis. In total we included 2,311
cases and 11,555 controls in the analyses (Table 2).
Statistical analysis
As the main predictor variables in the models we used
contraceptive use and family history of VTE. Contracep-
tive use was defined as described above; however, in
order to be defined as a user cases had to be using con-
traceptives at the time of their VTE diagnosis. Controls
had to be using contraceptives on the day of the VTE
diagnosis in the corresponding case. Family history was
defined as any type of VTE (see definition above) among
first-degree relatives (mother, father and/or sibling(s)).
The VTE in relatives had to be registered prior to the
contraceptive prescription date for the case/control and
in situations where the individual had no contraceptive
use prior to the date of the VTE diagnosis in cases.
We used conditional logistic regression in order to
study the effects of contraceptives, family history of VTE
and their interaction on VTE. In models A1 and A2 we
separately investigated the effects of contraceptives and
family history of VTE on VTE, respectively. In model B
we included both variables in the same model. Model C




(1) Antithrombotic agent within 14 days 2,964 -
(2) Father and mother were not registered
in the Multi-Generation Register
971 404,747
(3) Individuals with previously registered
diagnoses of any type of VTE
1,560 15,334




(4) Sterilization 242 29.331
(4) Coronary heart disease/Heart failure/
Cerebrovascular disease
191 6,915
(5) Cancer 373 8,957
(6) Infertility 240 37,239
(7) Pregnancy 343 56,043
(8) Women who stopped use of any
contraceptives prior to the VTE diagnosis
982 312,099
Unable to match with 5 controls 98 -
Included in the analysis 2,311 11,555
Note that excluded and included patients will not sum up to 7,795 as VTE-
cases could be excluded due to several exclusion criteria
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also included the interaction between contraceptives and
family history of VTE. As the results from the condi-
tional logistic regression are on the multiplicative scale
we also used a hierarchical regression model (i.e., using
the identity link) in order to get the interaction results
on an additive scale.
In additional analyses, using conditional logistic re-
gression, we investigated whether different generations
of combined oral contraceptives had different effects.
Both fixed combination (G03AA) and sequential prepa-
rations (G03AB) were considered. Contraceptives were
categorized into five groups according progestogen content
[43]: first-generation progesterone (ATC codes: G03AA03
[lynestrenol, G03AA05 [norethisterone], G03AA01 [ethyno-
diol], G03AB02 [lynestrenol], G03AB04 [norethisterone]);
second-generation progesterone (ATC codes: G03AA06
[norgestrel], G03AA07 [levonorgestrel], G03AB03 [levonor-
gestrel]); third-generation progesterone (G03AA09 [desoges-
trel], G03AA11 [norgestimate], G03AB05 [desogestrel],
G03AB06 [gestodene]); fourth-generation progesterone
(ATC code: G03AA12 [drospirenone]); and undefined (ATC
code: G03AA14 [nomegestrol]). In the models we created
one term for contraceptives (yes/no) and one categorical
variable defining each generation. We used the first gener-
ation as the reference in the analysis. Furthermore, we ex-
plored whether the effect of contraceptives on VTE was
stronger among individuals who were newly prescribed con-
traceptives. We arbitrarily use 6 months prior to the date of
VTE diagnosis as the cut-off. Individuals who had used con-
traceptives for less than 6 months were defined as new
users. Finally, we investigated whether the effect of contra-
ceptives was different for diagnosis of VTE at different ages.
We included an interaction term between contraceptives
and age at VTE diagnosis (mean 36.4 years). In the models
the main effect of age is not included but only the inter-
action between COC use and age [44]. All statistical analyses
were performed in SAS 9.3.
Results
Table 3 shows descriptive statistics for all 2,311 included
female VTE patients in the Swedish population (age 15-49
years) and the 11,555 controls (matched on age and
education level). The mean age of cases was 36.4 years
(standard deviation 9.5). Both among controls (14.6 % vs.
4.5 %; p <0.0001) and cases (27.2 % vs. 8.8 %; p <0.0001)
oral contraceptive use was more common in women with-
out a family history of VTE compared with women with a
family history of VTE.
Risk of VTE in COC users and women with a family history
of VTE
Table 4 shows ORs for VTE. In model A1 COC use gave
an OR of 2.40 for VTE. In model A2 family history of
VTE gave an OR of 2.23 for VTE. In the combined model
B, the ORs for VTE were significant for both COC use
(OR = 2.53) and family history of VTE (OR = 2.38). Model
C included an interaction term. However, there was no
significant multiplicative interaction between COC use
and family history of VTE. Table 5 shows the results from
the hierarchical regression model. There was no signifi-
cant additive interaction between family history of VTE
and COC use. The OR for COC users with a family his-
tory of VTE was 6.02 (95 % CI 5.02; 7.22). The OR of 6.02
is the OR for COC users with a family history compared
to non-COC users without a family history (Model B in
Table 4 (2.53*2.38)).
Different generations of COCs
Table 6 shows the results for risk of VTE for different gener-
ations of COCs. Only generation 4 had a significant higher
OR than generation 1. The estimated OR was highest for
generation 4 (OR= 3.58). Additional file 2: Table S2 shows
the frequency of family history of VTE for different genera-
tions of COC. The frequency of family history of VTE for
users of the different generations of COCs was as follows:
first generation 3.71 %, second generation 3.17 %, third
generation 3.45 %, fourth generation 3.18 % and undefined
generation 4.99 %. Thus, the increased OR for generation
4 was not explained by family history of VTE.
New users of COC
Table 7 shows the risk of VTE according to time from
start of COC use. There was a significant interaction
between COC use and new users of COC. This means
Table 3 Descriptive statistics for all 2,311 females (age 15-49 years) with VTE in the Swedish population and their matched controls
CASES CONTROLSa
Contraceptives Contraceptives
No Yes All No Yes All
Age (years)b 36.4 (9.5)a
No VTE in relative 1,395 (72.9) 520 (27.2) 1,915 (82.9) 9,013 (85.5) 1,535 (14.6) 10,548 (91.3)
VTE in relative 361 (91.2) 35 (8.8) 396 (17.1) 962 (95.5) 45 (4.5) 1,007 (8.7)
1,756 (76.0) 555 (24.0) 2,311 9,975 (86.3) 1,580 (13.7) 11,555
Numbers of cases are shown with percentages in brackets. aControls were
matched on age and education. bThe mean age (standard deviation within brackets)
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that the risk of VTE was highest during the first 6 months
of COC use (OR = 3.53), compared to an increased odds of
2.12 if you had used COC for more than 6 months.
Age and COC use
Table 8 shows the testing for interaction between COC
use and age. There was no interaction between COC use
and age (Table 8). Thus, the OR is independent of the age.
Sensitivity analysis
In Table 9, a sensitivity analysis including all potential cases
(7,795) matched to 5 controls is presented. The results are
not different to any major degree compared to the main
results after exclusions presented in Table 4.
Discussion
Main findings
In this study we showed that family history of VTE is an
independent risk factor for VTE among COC users. The
effects of family history of VTE and use of COC were
quite similar (OR ~2.5) (Table 4). We did not find an
interaction between family history of VTE and COC use
(Tables 4 and 5). The lack of interaction indicates that
the risk of COC use in women with family history of
VTE is determined by the product of the odds ratios for
family history and COC use. This is similar as for the
combination of COC use and carriership of Factor V
Leiden [18, 19]. However, this could be due to the fact
that among the 2,311 individuals with VTE, only 35 had
both a family history of VTE and were COC users.
Interestingly, the prevalence of family history of VTE was
lower among COC users (both controls and cases) com-
pared to non-COC users, suggesting that clinicians in
Sweden consider family history of VTE when prescribing
COCs. As Swedish clinicians do not prescribe COCs to
women with a family history of VTE to a high extent, the
result may be an underestimation of the importance of fam-
ily history of VTE.
Strengths and limitations
The present study has a number of strengths. These in-
clude nationwide coverage in a country of high medical
standards, and diagnosis of patients by specialists during
extended examinations in clinics [38–41]. Data in the
Swedish registers are remarkably complete. In 2001, per-
sonal numbers were missing in only 0.4 % of hospitalisa-
tions and main diagnoses in 0.9 % of hospitalisations
[38]. The Swedish Hospital Discharge Register was
started in 1964, and has had nationwide coverage since
1987. Thus, the information on the exposure was
complete and had been gathered for purposes other than
scientific analysis, eliminating the recall bias that is com-
mon in case-control studies [39]. Importantly, the Multi-
Generation Register is a validated source that has been
proved to be reliable in the study of many familial dis-
eases [39–42]. Furthermore, we eliminated the problem
of left censoring by measuring use of combined oral
contraceptives over a 6 month period before our study
started. The Swedish Hospital Discharge Register has
nearly 90 % overall validity [38–41]. The validity for car-
diovascular disorders such as VTE, myocardial infarction
and stroke is around 95 % [38–41, 45, 46]. The Swedish
Table 4 Results from the conditional logistic regression analysis
of 2,311 females (age 15-49 years) with VTE in the Swedish
population and their matched controls
Model A1 and A2 Model B Model C
Odds ratio Odds ratio Odds ratio
Contraceptives 2.40 (2.12-2.72)a 2.53 (2.23-2.87) 2.54 (2.23-2.90)




In models A1a and A2b we separately investigated the effect of contraceptives and
family history of VTE, respectively, on VTE. Model B included both variables. Model
C also included the interaction between contraceptives and family history of VTE.
*=times sign.
Table 5 Test for additive interaction between family history of
VTE and COC use
Beta (SE)
Contraceptives 0.12 (0.009)
VTE in relative 0.14 (0.011)
Interaction between VTE in relative and Contraceptives 0.05 (0.043)a
Results from a regression model with an identity link for 2,311 females (age
15-49 years) with VTE in the Swedish population and their matched controls
aThere was no significant additive interaction between family history of VTE
and COC use, p-value was 0.27
Table 6 VTE risk for contraceptives containing different
generations of progestogens
OR (95 % CI) Estimated OR
Generation 1 Ref 2.00 (1.44-2.79)
Generation 2 1.04 (0.74-1.48) 2.09 (1.29-3.37)a
Generation 3 1.23 (0.84-1.80) 2.46 (1.48-4.09)a
Generation 4 1.79 (1.22-2.62) 3.58 (2.16-5.93)a
Undefined generation 1.64 (0.52-5.15) 3.29 (1.00-10.82)a
Results from conditional logistic regression for 2,311 females with VTE in the
Swedish population and their matched controls
aCalculated by multiplying the term (i.e., 1.04, 1.23, 1.79, and 1.64, respectively)
for each generation and the term that defines use of contraceptives (i.e.; 2.00)
Table 7 Risk of VTE according to duration of COC use
OR (95 % CI) Estimated OR
Contraceptives 2.12 (1.84-2.44)
Users of COC for more than 6 months Ref 2.12 (1.84-2.44)
New Users of COC 1.67 (1.33-2.09)a 3.53 (2.56-4.36)
Results from conditional logistic regression for 2,311 females (age 15-49 years)
with VTE in the Swedish population and their matched controls
aInteraction between COC use and new users of COC
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outpatient register however, has not been validated. We
were able to validate venous thromboembolic events by
linking individual data on diagnoses to data on subse-
quent anticoagulation therapy. We restricted the analysis
to cases that retrieved from the pharmacy an anti-
thrombotic agent within 14 days from the date of their
VTE diagnosis, which makes diagnosis of VTE highly
probable.
This study does, however, have some limitations. We
could not control for body mass index and smoking. We
did not have access to data for thrombophilic defects,
but family history is known to be a risk factor for VTE
even in the presence of thrombophilia [30]. It is also
possible that we underestimated the importance of fam-
ily history as the present data suggest that COCs are less
often prescribed to women with a family history of VTE.
Thus, our study is conservative in its estimation of the
importance of family history of VTE in COC users. We
used a washout period of 6 months to include only
women with new prescriptions of COC. However, we do
not know if the included women used COCs before the
washout period.
Interpretation
Our results are in agreement with a previous case-control
study [37]. That study showed a higher risk of VTE for
the combination of family history of VTE and COC use
than in the present study (OR = 15.3 vs. OR = 6.02). This
might be due to the fact that COC use was a stronger risk
factor for VTE in that study than in the present study,
possibly due to recall and selection bias in the previous
study. Our findings are also in agreement with previous
reports that COCs have a multiplicative impact on indi-
viduals with thrombophilic defects [18–26]. However, only
30 % of VTE cases with a family history of VTE are ex-
plained by the known major thrombophilic defects [30].
The occurrence of VTE in patients with a positive family
history of VTE is likely to have an important genetic con-
tribution [30–35]. Thus, family history may signal the
presence of unknown genetic defects in the family, which
may increase the risk of VTE in women using COCs.
Another result in the present study worth mentioning
is our confirmation of previous findings that the OR for
VTE is highest during the initial period after starting
COC use, with a significant interaction between COC
use and duration of COC use (Table 7) [47, 48]. The cause
of this interaction remains to be determined. We also in-
vestigated whether the prothrombotic effect of COC use
differed depending on age. There was no interaction be-
tween COC use and age, indicating that the prothrombo-
tic effect of COC use on VTE risk was independent of
age. However, as the absolute VTE risk increases with age,
older women using COCs will have a higher absolute risk
of VTE than younger women using COCs [48].
Another subject of interest is whether the VTE risk asso-
ciated with COC use is dependent on progesterone content
[16, 49]. In the present study only COCs containing dros-
pirenone (i.e. fourth-generation COCs) had higher ORs
than COCs containing first-generation progesterone.
The present study confirms recent studies indicating an in-
creased risk of VTE for COCs containing drospirenone
[50, 51]. However, the subgroup analysis should be inter-
preted with caution because the present study suggests that
clinicians take VTE risk factors such as family history of
VTE into account when prescribing COCs. We found no
significant difference between COCs containing first- and
second-generation progestogens or between COCs con-
taining first- and third-generation progestogens. Several
previous reports found a higher risk of VTE for COCs con-
taining third- compared to second-generation progesto-
gens [2–4, 9, 12, 19], and clinicians might therefore be less
prone to prescribe COCs containing third-generation pro-
gestogens to women whom they think have an increased
risk of VTE. Farmer et al. found no increased risk of VTE
for third-generation compared to second-generation
oral contraceptives [5]. Shapiro and Dinger suggest that
the increased risk of VTE in COC users is a class effect
independent of the progestogen used [52]. The third-
generation progestogen norgestimate is difficult to classify
as it is partly converted to levonorgestrel in the human
body [53]. It is therefore sometimes classified as a second-
generation progestogen. In the present study we included
norgestimate among the third-generation progestogens.
The increased VTE risk for fourth-generation COCs was
not due to an increased prevalence of family history of
VTE in users of fourth-generation COCs (Additional file 2:
Table S2).
Conclusion
Family history of VTE is a risk factor for VTE in
women using COCs. The lower prevalence of COC
Table 8 Testing for interaction between COC use and age
OR (95 % CI)
Contraceptives 2.40 (2.08-2.76)
Interaction between COC use with age 1.00 (0.99-1.01)
Results from conditional logistic regression for 2,311 females (age 15-49 years)
with VTE in the Swedish population and their matched controls
Table 9 Sensitivity analysis including all potential cases (7,795)
matched to 5 controls
Model A1 and A2 Model B Model C
Odds ratio Odds ratio Odds ratio
Contraceptives 1.92 (1.76-2.10) 2.00 (1.82-2.18) 1.97 (1.80-2.16)
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use among women with a family history of VTE sug-
gests that family history of VTE is considered to
some degree when COCs are prescribed in Sweden.
The lack of interaction indicates that the risk of
COC use in women with family history of VTE is
determined by the product of the odds ratios for
family history and COC use. Although the present
study was limited to Sweden, the Swedish population
is genetically closely related to German and British
people, and the results from Swedish nationwide
family studies are likely to be valid for many persons
of white origin in Europe and the United States [39].
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Additional file 1: Table S1. ICD-7, ICD-8, ICD-9 and ICD-10 codes used to
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Additional file 2: Table S2. Family history of VTE in relation to different
generations of COC. (DOCX 51 kb)
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